Navigation Links
WuXi PharmaTech Announces Second-Quarter 2010 Results
Date:8/1/2010

1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for third- quarter 2010 and full-year 2010 and prospects generally, anticipated customer benefits of our integrated R&D platform, expected strong performance of all our businesses and industry trends favoring outsourcing and offshoring R&D, are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, potential customer, employee and management distraction following the termination of our proposed combination with Charles River Laboratories, continued uncertainty in the global economy, the pressures being felt by our customers, and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced and offshored R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients and may be unable to successfully expand our capabilities to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include failure to generate sufficient future cash flows or to secure any
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
2. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
3. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
4. WuXi PharmaTech Announces First-Quarter 2010 Results
5. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
8. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
9. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
10. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
(Date:7/26/2014)... Studio B Dental in Toronto now offers All-on-Four dental ... a Day, gives patients the opportunity to replace their damaged ... whites with very little recovery time and no bone grafting. ... like natural teeth, and require no special care beyond the ... is one of the premiere dental experts on All-on-Four implants ...
(Date:7/26/2014)... According to the Banish My Bumps Pdf review ... that covers detailed instructions on how to eliminate ... any medication. , Vkool reveals in its review ... for relieving symptoms of keratosis pilaris quickly. In addition, ...     How to treat children's keratosis pilaris ,     How ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 PersonalInjurySolicitorsIreland, ... legal help to people who have suffered from ... launch of both their new company, and a ... on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , ... The focus of the company is always on ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 American ... accidents or unexpected collisions can pay higher premiums for ... enhanced its local insurer network to provide SR22 insurance ... . , The different coverage network of local ... has expanded the search platform now publicly available for ...
(Date:7/25/2014)... Ohio (PRWEB) July 25, 2014 Consuming ... foods? How to know? , Read the labels! , ... and determine how it relates to health during a ... p.m. Aug. 1 at Humility House, 755 Ohltown Road, ... will lead an informational discussion and answer questions. ...
Breaking Medicine News(10 mins):Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Learn to Decipher Food Labels at Humility House 2
... had developed new technology to use transistors in devices ... ,The biosensor technology was developed by a ... Science and Technology. ,"We proved that transistors ... for devices that convert biological responses into electrical signals," ...
... First Lady of the United States, Laura Bush arrived in the ... Africa tour to bolster the US government's anti AIDS and malaria ... President Abdoulaye Wade's wife Viviane. ,From Senegal she is ... a five-day long trip to the continent which will also focus ...
... study published on bmj.com today (Tuesday 26 June) ... patients with well-controlled, non-insulin dependent (type 2) diabetes. ... the American Diabetes Association Conference, suggests that current ... reviewed. ,Non-insulin dependent (type 2) diabetes ...
... observed as the National Testing Day in the US. ... produced by the National Association of People with AIDS ... HIV counseling and testing. ,The Centers for ... 280,000 people nationwide are HIV-positive but are unaware of ...
... celebrating annual Monsoon festival, which marks San Joao, the feast ... a legacy Goans have inherited from the Portuguese, who ruled ... ,During the celebrations, Goans jumped into rivers, ponds and wells ... celebrated with much traditional fervour. ,At Loutulim in ...
... for Evolutionary Anthropology, Leipzig, Germany, have investigated evidence of ... about altruism are often based on the assumption that ... human version differs from that of other animals in ... colleagues have found evidence that chimpanzees act altruistically toward ...
Cached Medicine News:Health News:Questions Over Value of Glucose Monitoring for Non-insulin Using Diabetes Patients 2Health News:US Officials Urge Testing for HIV as Health Crisis Intensifies 2Health News:US Officials Urge Testing for HIV as Health Crisis Intensifies 3Health News:Goans Celebrate Monsoon Festival 2